Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Novel microbiome signature may detect NAFLD-cirrhosis

Key clinical point: A novel stool microbiome–derived signature may help detect cirrhosis in patients with nonalcoholic fatty liver disease.

Major finding: In a cohort of probands, the microbial biomarker showed strong diagnostic accuracy with an area under the ROC curve of 0.92.

Study details: A cross-sectional analysis of 203 patients with nonalcoholic fatty liver disease.

Disclosures: The study was supported by funding from the National Institutes of Health and Janssen. The authors reported financial affiliations with the American Gastroenterological Association, Atlantic Philanthropies, the John A. Hartford Foundation, and the Association of Specialty Professors.

Citation:

Caussy C et al. Nat Commun. 2019 Mar 29. doi: 10.1038/s41467-019-09455-9.